SANOFI.NS Stock Analysis
SA
Neutral
Based on Eyestock quantitative analysis, SANOFI.NS`s fundamental data and valuation indicate an investment grade of Neutral at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Moderate score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Overvalued
Market cap $B
1.468
Dividend yield
1.92 %
Shares outstanding
23.03 B
Sanofi India Ltd. engages in the manufacturing and distribution of pharmaceutical drugs. The company is headquartered in Mumbai, Maharashtra and currently employs 3,530 full-time employees. The firm is primarily engaged in the business of manufacturing and trading of drugs and pharmaceuticals. The company offers a range of medicines and supplements for treatment of diabetes (both insulin and orals), cardiology, thrombosis, epilepsy, allergies, and infections. The company has two manufacturing sites, one in Hyderabad and one in Goa. Its geographical segments include India, Singapore, and Others. The company sells its products through independent distributors primarily in India. The company also manufactures its products through third party manufacturers. The different types of dosage forms include tablets, capsules (hard and soft), eye/ear drops, ampoules, vials, creams, and ointment. Its brands include Lantus, Allegra, and Combiflam. Its vaccine products include Adacel, Avaxim 80U/160U, FluQuadri, Hexaxim, Menactra, Tetraxim, Vaxigrip, Stamaril, Shanvac-B and ShanTT. Its consumer healthcare products include Allegra, Allegra nasal, and Avil.